{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:23:54Z","timestamp":1789842234625,"version":"4.0.1"},"reference-count":193,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["ZDBS-ZRKJZ-TLC005"],"award-info":[{"award-number":["ZDBS-ZRKJZ-TLC005"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010574","name":"China Academy of Space Technology","doi-asserted-by":"publisher","award":["2022QNRC001"],"award-info":[{"award-number":["2022QNRC001"]}],"id":[{"id":"10.13039\/501100010574","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82025032"],"award-info":[{"award-number":["82025032"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073773"],"award-info":[{"award-number":["82073773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.apsb.2024.02.019","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T21:13:07Z","timestamp":1709068387000},"page":"2006-2025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives"],"prefix":"10.1016","volume":"14","author":[{"given":"Bingwen","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-5339","authenticated-orcid":false,"given":"Miaorong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.02.019_bib1","unstructured":"Federation ID. IDF Diabetes Atlas-10th edition[EB\/OL]. Available from: https:\/\/diabetesatlas.org\/."},{"key":"10.1016\/j.apsb.2024.02.019_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cmet.2019.11.017","article-title":"New frontiers in the treatment of type 1 diabetes","volume":"31","author":"Warshauer","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2024.02.019_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.02.019_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.865782","article-title":"Extracellular vesicle therapy for type 1 diabetes","volume":"13","author":"Soltani","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.02.019_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.02.019_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endo"},{"key":"10.1016\/j.apsb.2024.02.019_bib7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2024.02.019_bib8","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/dom.14587","article-title":"Insulin centennial: milestones influencing the development of insulin preparations since 1922","volume":"24","author":"Owens","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.apsb.2024.02.019_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/193229680900300323","article-title":"Oral insulin and buccal insulin: a critical reappraisal","volume":"3","author":"Heinemann","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2024.02.019_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","article-title":"Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts","volume":"101","author":"Moroz","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib11","unstructured":"Jea F, Inventor. Oral blood sugar lowering compositions. US patent US3172814 A1965. 1965 March 9."},{"key":"10.1016\/j.apsb.2024.02.019_bib12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1023\/A:1013362227548","article-title":"Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats","volume":"18","author":"Suarez","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2024.02.019_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/1932296814529988","article-title":"Oral insulin reloaded: a structured approach","volume":"8","author":"Zijlstra","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2024.02.019_bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/jphp.12607","article-title":"Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities","volume":"68","author":"Wong","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2024.02.019_bib15","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.02.019_bib16","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.apsb.2024.02.019_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.apsb.2024.02.019_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-like peptide-1 receptor agonist use in people living with type 2 diabetes mellitus and chronic kidney disease: a narrative review of the key evidence with practical considerations","volume":"13","author":"Gorriz","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.apsb.2024.02.019_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.02.019_bib20","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.02.019_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist","volume":"22","author":"Bucheit","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.apsb.2024.02.019_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.drudis.2021.01.020","article-title":"New perspectives in oral peptide delivery","volume":"26","author":"Zizzari","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2024.02.019_bib23","series-title":"Drug trials snapshot: LUPKYNIS","year":"2021"},{"key":"10.1016\/j.apsb.2024.02.019_bib24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/17425247.2021.1942838","article-title":"Transient Permeation Enhancer(R) (TPE(R)) technology for oral delivery of octreotide: a technological evaluation","volume":"18","author":"Brayden","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2024.02.019_bib25","unstructured":"Diasome P. Study of two doses of oral HDV-insulin and placebo with background metformin treatment in patients with type 2 diabetes mellitus. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT00814294."},{"key":"10.1016\/j.apsb.2024.02.019_bib26","author":"Oramed"},{"key":"10.1016\/j.apsb.2024.02.019_bib27","author":"Oramed"},{"key":"10.1016\/j.apsb.2024.02.019_bib28","unstructured":"Oramed. Oramed announces that its Chinese partner, HTIT, has successfully completed a phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. 05\/15\/2023. Available from: https:\/\/www.prnewswire.com\/news-releases\/oramed-announces-that-its-chinese-partner-htit-has-successfully-completed-a-phase-3-oral-insulin-clinical-trial-and-submitted-a-marketing-authorization-application-in-china-301824604.html."},{"key":"10.1016\/j.apsb.2024.02.019_bib29","unstructured":"Bows Pharmaceuticals AG. A two part study of peroral insulin in type 2 diabetes. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT00990444."},{"key":"10.1016\/j.apsb.2024.02.019_bib30","unstructured":"Oshadi Drug A. Safety and tolerability of oshadi lcp in patients with type 1 diabetes mellitus\u2015phase Ib clinical study. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT01772251."},{"key":"10.1016\/j.apsb.2024.02.019_bib31","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral delivery of proteins and peptides: challenges, status quo and future perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpb.2012.07.014","article-title":"pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide\/protein drugs and poorly water-soluble drugs","volume":"82","author":"Wang","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/17425247.2014.924500","article-title":"Orally active-targeted drug delivery systems for proteins and peptides","volume":"11","author":"Li","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2024.02.019_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8227(99)00099-6","article-title":"Injection related anxiety in insulin-treated diabetes","volume":"46","author":"Zambanini","year":"1999","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.apsb.2024.02.019_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.618411","article-title":"Advances in oral drug delivery","volume":"12","author":"Alqahtani","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.02.019_bib36","article-title":"A review on bioengineering approaches to insulin delivery: a pharmaceutical and engineering perspective","volume":"19","author":"Taraghdari","year":"2019","journal-title":"Macromol Biosci"},{"key":"10.1016\/j.apsb.2024.02.019_bib37","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1021\/acs.molpharmaceut.6b00168","article-title":"Proinsulin-transferrin fusion protein exhibits a prolonged and selective effect on the control of hepatic glucose production in an experimental model of type 1 diabetes","volume":"13","author":"Shao","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jphp.12852","article-title":"Oral insulin delivery: existing barriers and current counter-strategies","volume":"70","author":"Gedawy","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2024.02.019_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155142","article-title":"Insulin: the master regulator of glucose metabolism","volume":"129","author":"Norton","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.apsb.2024.02.019_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2024.02.019_bib41","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.02.019_bib43","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.apsb.2019.01.004","article-title":"Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides\/proteins","volume":"9","author":"Han","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-5173(01)00871-7","article-title":"Enteric coated HPMC capsules designed to achieve intestinal targeting","volume":"231","author":"Cole","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib45","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/j.apsb.2022.06.006","article-title":"Site-selective oral delivery of therapeutic antibodies to the inflamed colon via a folic acid-grafted organic\/inorganic hybrid nanocomposite system","volume":"12","author":"Lee","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib46","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.addr.2011.08.005","article-title":"Microgels and microcapsules in peptide and protein drug delivery","volume":"63","author":"Bysell","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1248\/yakushi.127.813","article-title":"[Design of nanohydrogel-incorporated microcapsules for appropriate controlled-release of peptide drugs]","volume":"127","author":"Ichikawa","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.apsb.2024.02.019_bib48","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1023\/A:1018968611962","article-title":"Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats","volume":"11","author":"Yamamoto","year":"1994","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2024.02.019_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107537","article-title":"Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs","volume":"211","author":"Yamamoto","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2024.02.019_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.2042-7158.1994.tb03712.x","article-title":"Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers\u00a0and protease inhibitors in rats","volume":"46","author":"Yamamoto","year":"1994","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2024.02.019_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.addr.2017.10.009","article-title":"The role of mucus on drug transport and its potential to affect therapeutic outcomes","volume":"124","author":"Murgia","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.apsb.2016.03.003","article-title":"Sodium dodecyl sulfate\/beta-cyclodextrin vesicles embedded in chitosan gel for insulin delivery with pH-selective release","volume":"6","author":"Li","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800341","article-title":"Prevention of type 1 diabetes with acetalated dextran microparticles containing rapamycin and pancreatic peptide P31","volume":"7","author":"Chen","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1021\/nn507097k","article-title":"Artificial micromotors in the mouse's stomach: a step toward in\u00a0vivo use of synthetic motors","volume":"9","author":"Gao","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib55","doi-asserted-by":"crossref","first-page":"8397","DOI":"10.1021\/acsnano.8b03760","article-title":"Micromotor pills as a dynamic oral delivery platform","volume":"12","author":"Karshalev","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib56","doi-asserted-by":"crossref","first-page":"1705640","DOI":"10.1002\/adfm.201705640","article-title":"Micromotors go in\u00a0vivo: from test tubes to live animals","volume":"28","author":"de \u00c1vila","year":"2017","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib57","doi-asserted-by":"crossref","first-page":"eaam6431","DOI":"10.1126\/scirobotics.aam6431","article-title":"Micro\/Nanorobots for biomedicine: delivery, surgery, sensing, and detoxification","volume":"2","author":"Li","year":"2017","journal-title":"Sci Robot"},{"key":"10.1016\/j.apsb.2024.02.019_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jps.24182","article-title":"Microneedles for drug delivery via the gastrointestinal tract","volume":"104","author":"Traverso","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2024.02.019_bib59","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nmat4355","article-title":"A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices","volume":"14","author":"Zhang","year":"2015","journal-title":"Nat Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib60","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1007\/s11356-021-17346-0","article-title":"Emergence of microneedles as a potential therapeutics in diabetes mellitus","volume":"29","author":"Zahoor","year":"2022","journal-title":"Environ Sci Pollut Res Int"},{"key":"10.1016\/j.apsb.2024.02.019_bib61","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1021\/acsami.5b03555","article-title":"N-Trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption","volume":"7","author":"Sheng","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2024.02.019_bib62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib64","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpharm.2016.01.022","article-title":"Insulin loaded mucus permeating nanoparticles: addressing the surface characteristics as feature to improve mucus permeation","volume":"500","author":"de Sousa","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib65","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.1021\/acsami.1c00580","article-title":"Virus-mimicking mesoporous silica nanoparticles with an electrically neutral and hydrophilic surface to improve the oral absorption of insulin by breaking through dual barriers of the mucus layer and the intestinal epithelium","volume":"13","author":"Zhang","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2024.02.019_bib66","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.biomaterials.2006.11.008","article-title":"Superporous hydrogels containing poly(acrylic acid-co-acrylamide)\/O-carboxymethyl chitosan interpenetrating polymer networks","volume":"28","author":"Yin","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.actbio.2017.01.016","article-title":"pH-sensitive peptide hydrogel for glucose-responsive insulin delivery","volume":"51","author":"Li","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2024.02.019_bib68","doi-asserted-by":"crossref","first-page":"100110","DOI":"10.1016\/j.medidd.2021.100110","article-title":"Engineering nanoparticles to overcome the mucus barrier for drug delivery: design, evaluation and state-of-the-art","volume":"12","author":"Liu","year":"2021","journal-title":"Med Drug Discovery"},{"key":"10.1016\/j.apsb.2024.02.019_bib69","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.02.019_bib70","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1016\/j.biomaterials.2013.08.048","article-title":"Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles","volume":"34","author":"Li","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801123","article-title":"Protein corona liposomes achieve efficient oral insulin delivery by overcoming mucus and epithelial barriers","volume":"8","author":"Wang","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib72","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41565-020-0693-6","article-title":"Zwitterionic micelles efficiently deliver oral insulin without opening tight junctions","volume":"15","author":"Han","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2024.02.019_bib73","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.apsb.2020.12.019","article-title":"Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats","volume":"11","author":"Dahlgren","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib74","article-title":"Oral insulin delivery: barriers, strategies, and formulation approaches: a comprehensive review","volume":"242","author":"Shetty","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2024.02.019_bib75","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.02.019_bib76","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsami.8b00507","article-title":"Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin","volume":"10","author":"Xu","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2024.02.019_bib77","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.apsb.2017.11.007","article-title":"Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin","volume":"8","author":"He","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib78","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1080\/10717544.2022.2118399","article-title":"Enhanced oral absorption of insulin: hydrophobic ion pairing and a self-microemulsifying drug delivery system using a D-optimal mixture design","volume":"29","author":"Goo","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2024.02.019_bib79","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.apsb.2021.07.024","article-title":"The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib80","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.apsb.2020.11.001","article-title":"Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib81","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2005.07.142","article-title":"Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency","volume":"335","author":"Liang","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2024.02.019_bib82","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2174\/1381612826666201019102640","article-title":"Cell-penetrating peptides as a potential drug delivery system for effective treatment of diabetes","volume":"27","author":"Korivi","year":"2021","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2024.02.019_bib83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.peptides.2017.12.014","article-title":"Oral delivery of anti-diabetes therapeutics using cell penetrating and transcytosing peptide strategies","volume":"100","author":"Rehmani","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2024.02.019_bib84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41578-019-0156-6","article-title":"Materials for oral delivery of proteins and peptides","volume":"5","author":"Brown","year":"2019","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib85","doi-asserted-by":"crossref","first-page":"19787","DOI":"10.1002\/anie.202008879","article-title":"Oral insulin delivery platforms: strategies to address the biological barriers","volume":"59","author":"Xiao","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2024.02.019_bib86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1461-5347(99)00142-X","article-title":"Transcellular uptake mechanisms of the intestinal epithelial barrier Part one","volume":"4","author":"Daugherty","year":"1999","journal-title":"Pharm Sci Technol Today"},{"key":"10.1016\/j.apsb.2024.02.019_bib87","doi-asserted-by":"crossref","first-page":"14161","DOI":"10.1021\/acsnano.3c04897","article-title":"Bioinspired pH-responsive microalgal hydrogels for oral insulin delivery with both hypoglycemic and insulin sensitizing effects","volume":"17","author":"Ren","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib89","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.apsb.2021.02.020","article-title":"In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions","volume":"11","author":"Martinez-Lopez","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrgastro.2013.35","article-title":"The gastrointestinal mucus system in health and disease","volume":"10","author":"Johansson","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2024.02.019_bib91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib92","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.drudis.2016.04.007","article-title":"Intracellular transport of nanocarriers across the intestinal epithelium","volume":"21","author":"Fan","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2024.02.019_bib93","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijbiomac.2019.02.094","article-title":"Breaking the barricade of oral chemotherapy through polysaccharide nanocarrier","volume":"130","author":"Dey","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2024.02.019_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100064","article-title":"Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration","volume":"8","author":"Nguyen","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.apsb.2024.02.019_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/srep32301","article-title":"Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics","volume":"6","author":"Lonn","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2024.02.019_bib97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41551-020-0572-3","article-title":"An optimized antigen-protein fusion","volume":"4","author":"Romero","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2024.02.019_bib98","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2024.02.019_bib99","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1039\/C9NR03025E","article-title":"Biological fate of ingested lipid-based nanoparticles: current understanding and future directions","volume":"11","author":"Wang","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2024.02.019_bib100","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/molecules27092961","article-title":"Bile acids transporters of enterohepatic circulation for targeted drug delivery","volume":"27","author":"Durnik","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.02.019_bib101","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jconrel.2022.11.010","article-title":"Ligand-modified nanocarriers for oral drug delivery: challenges, rational design, and applications","volume":"352","author":"Zhang","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2024.02.019_bib102","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2018.183","article-title":"Non-invasive delivery strategies for biologics","volume":"18","author":"Anselmo","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.02.019_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114463","article-title":"The in\u00a0vivo fate of polymeric micelles","volume":"188","author":"Cai","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Thi","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.apsb.2024.02.019_bib106","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1021\/acsnano.8b09681","article-title":"Oriented assembly of cell-mimicking nanoparticles via a molecular affinity strategy for targeted drug delivery","volume":"13","author":"Xie","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib107","article-title":"Liver-target and glucose-responsive polymersomes toward mimicking endogenous insulin secretion with improved hepatic glucose utilization","volume":"30","author":"Wang","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib108","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1038\/s41467-022-34357-8","article-title":"Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.02.019_bib109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2017.03.015","article-title":"Novel strategies in the oral delivery of antidiabetic peptide drugs\u2015Insulin, GLP 1 and its analogs","volume":"115","author":"Ismail","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101063","article-title":"Delivery of therapeutic agents and cells to pancreatic islets: towards a new era in the treatment of diabetes","volume":"83","author":"Zeynaloo","year":"2022","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.apsb.2024.02.019_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120209","article-title":"Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment","volume":"255","author":"Xu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib112","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.drudis.2020.01.008","article-title":"Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities","volume":"25","author":"Raval","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2024.02.019_bib113","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/ph15121585","article-title":"Gastrointestinal permeation enhancers for the development of oral peptide pharmaceuticals","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.apsb.2024.02.019_bib114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/pharmaceutics11010041","article-title":"Application of permeation enhancers in oral delivery of macromolecules: an update","volume":"11","author":"Maher","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2024.02.019_bib115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425247.4.3.275","article-title":"Progress in absorption enhancers based on tight junction","volume":"4","author":"Kondoh","year":"2007","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2024.02.019_bib116","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endo"},{"key":"10.1016\/j.apsb.2024.02.019_bib117","first-page":"739","article-title":"Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells","volume":"272","author":"Tomita","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2024.02.019_bib118","first-page":"362","article-title":"Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells","volume":"284","author":"Lindmark","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2024.02.019_bib119","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s11095-007-9527-6","article-title":"Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in\u00a0vitro","volume":"25","author":"Feighery","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2024.02.019_bib120","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.cclet.2021.10.023","article-title":"The complexation of insulin with sodium N-[8-(2-hydroxybenzoyl)amino]-caprylate for enhanced oral delivery: effects of concentration, ratio, and pH","volume":"33","author":"Weng","year":"2022","journal-title":"Chinese Chem Lett"},{"key":"10.1016\/j.apsb.2024.02.019_bib121","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1023\/A:1012192115828","article-title":"Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers","volume":"14","author":"Brayden","year":"1997","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2024.02.019_bib122","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejps.2005.03.003","article-title":"Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method","volume":"25","author":"Hess","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2024.02.019_bib123","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ajhp\/zxaa413","article-title":"Management of type 2 diabetes with oral semaglutide: practical guidance for pharmacists","volume":"78","author":"Kane","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.apsb.2018.01.013","article-title":"Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery","volume":"8","author":"Wagner","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.02.019_bib125","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3390\/polym12112499","article-title":"Progress in the development of chitosan based insulin delivery systems: a systematic literature review","volume":"12","author":"Barbosa","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.apsb.2024.02.019_bib126","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijbiomac.2014.08.040","article-title":"pH-sensitive chitosan\/alginate core-shell nanoparticles for efficient and safe oral insulin delivery","volume":"72","author":"Mukhopadhyay","year":"2015","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2024.02.019_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119736","article-title":"Optimization of phytic acid-crosslinked chitosan microspheres for oral insulin delivery using response surface methodology","volume":"588","author":"Kim","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib128","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.biomaterials.2004.06.020","article-title":"Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption","volume":"26","author":"Smith","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib129","article-title":"Recent advances in ionic liquids in biomedicine","volume":"8","author":"Curreri","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2024.02.019_bib130","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1073\/pnas.1722338115","article-title":"Ionic liquids for oral insulin delivery","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.02.019_bib131","doi-asserted-by":"crossref","first-page":"2002912","DOI":"10.1002\/adfm.202002912","article-title":"Ionic liquids and deep eutectic solvents for enhanced delivery of antibodies in the gastrointestinal tract","volume":"31","author":"Angsantikul","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib132","doi-asserted-by":"crossref","first-page":"10622","DOI":"10.1039\/C8CC06397D","article-title":"Choline ionic liquid enhances the stability of Herceptin(R) (trastuzumab)","volume":"54","author":"Reslan","year":"2018","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.apsb.2024.02.019_bib133","doi-asserted-by":"crossref","first-page":"25298","DOI":"10.1039\/D1CP03349B","article-title":"The molecular mechanism behind the stabilization of insulin by choline and geranate (CAGE) ionic liquids - computational insights into oral insulin drug formulation","volume":"23","author":"Palanisamy","year":"2021","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.apsb.2024.02.019_bib134","article-title":"Choline-geranate deep eutectic solvent improves stability and half-life of glucagon-like peptide-1","volume":"4","author":"Agatemor","year":"2020","journal-title":"Adv Thera"},{"key":"10.1016\/j.apsb.2024.02.019_bib135","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s11095-022-03260-8","article-title":"Ionic liquids: promising approach for oral drug delivery","volume":"39","author":"Jiang","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2024.02.019_bib136","first-page":"392","article-title":"Advances in oral peptide drug nanoparticles for diabetes mellitus treatment","volume":"15","author":"Li","year":"2022","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib137","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/09506608.2022.2040293","article-title":"Critical material designs for mucus- and mucosa-penetrating oral insulin nanoparticle development","volume":"68","author":"Zaiki","year":"2022","journal-title":"Int Mater Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib138","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.addr.2016.07.007","article-title":"Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues","volume":"106","author":"Lundquist","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib139","doi-asserted-by":"crossref","first-page":"9826","DOI":"10.1016\/j.biomaterials.2011.08.087","article-title":"A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery","volume":"32","author":"Chen","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cis.2018.02.002","article-title":"Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: a review","volume":"253","author":"McClements","year":"2018","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.apsb.2024.02.019_bib141","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3390\/molecules24234209","article-title":"Nanoparticle delivery systems in the treatment of diabetes complications","volume":"24","author":"Souto","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.02.019_bib142","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2016.07.051","article-title":"Role of nanoparticle size, shape and surface chemistry in oral drug delivery","volume":"238","author":"Banerjee","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2024.02.019_bib143","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1021\/acs.nanolett.6b03515","article-title":"Rotation-facilitated rapid transport of nanorods in mucosal tissues","volume":"16","author":"Yu","year":"2016","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2024.02.019_bib144","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1021\/acsnano.5b03184","article-title":"Physical principles of nanoparticle cellular endocytosis","volume":"9","author":"Zhang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in\u00a0vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.apsb.2024.02.019_bib146","doi-asserted-by":"crossref","first-page":"20825","DOI":"10.1021\/acsnano.3c05853","article-title":"Size-dependent in\u00a0vivo transport of nanoparticles: implications for delivery, targeting, and clearance","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib147","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1166\/jnn.2013.7525","article-title":"Influence of nanoparticle shape, size, and surface functionalization on cellular uptake","volume":"13","author":"Ma","year":"2013","journal-title":"J Nanosci Nanotechnol"},{"key":"10.1016\/j.apsb.2024.02.019_bib148","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41551-019-0465-5","article-title":"Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability","volume":"4","author":"Lamson","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2024.02.019_bib149","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1021\/acs.nanolett.9b04841","article-title":"Enhanced transport of shape and rigidity-tuned alpha-lactalbumin nanotubes across intestinal mucus and cellular barriers","volume":"20","author":"Bao","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2024.02.019_bib150","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1073\/pnas.1818924116","article-title":"Temperature- and rigidity-mediated rapid transport of lipid nanovesicles in hydrogels","volume":"116","author":"Yu","year":"2019","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.02.019_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120323","article-title":"Tailored elasticity combined with biomimetic surface promotes nanoparticle transcytosis to overcome mucosal epithelial barrier","volume":"262","author":"Zheng","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib152","doi-asserted-by":"crossref","first-page":"9916","DOI":"10.1021\/acsami.7b16524","article-title":"Biomimetic viruslike and charge reversible nanoparticles to sequentially overcome mucus and epithelial barriers for oral insulin delivery","volume":"10","author":"Wu","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2024.02.019_bib153","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/acsnano.5b00028","article-title":"Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin","volume":"9","author":"Shan","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib154","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-018-05061-3","article-title":"Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers","volume":"9","author":"Yu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.02.019_bib155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.addr.2013.01.002","article-title":"Targeted nanoparticles with novel non-peptidic ligands for oral delivery","volume":"65","author":"Rieux","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib156","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2217\/nnm.16.43","article-title":"Transition from passive to active targeting of oral insulin nanomedicines: enhancement in bioavailability and glycemic control in diabetes","volume":"11","author":"Kaklotar","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.apsb.2024.02.019_bib157","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1021\/acsnano.8b07231","article-title":"Transferrin functionization elevates transcytosis of nanogranules across epithelium by triggering polarity-associated transport flow and positive cellular feedback loop","volume":"13","author":"Yang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2024.02.019_bib158","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007049","article-title":"Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery","volume":"5","author":"Pridgen","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.02.019_bib159","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41598-018-19170-y","article-title":"Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice","volume":"8","author":"Shi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2024.02.019_bib160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.18433\/J3J88Q","article-title":"Efficient peroral delivery of insulin via vitamin B12 modified trimethyl chitosan nanoparticles","volume":"18","author":"Ke","year":"2015","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.apsb.2024.02.019_bib161","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1091\/mbc.e07-07-0658","article-title":"Ca2+-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway","volume":"19","author":"Dickinson","year":"2008","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.apsb.2024.02.019_bib162","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2017.10.022","article-title":"Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery","volume":"151","author":"Fan","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2021.11.045","article-title":"Dual-modified nanoparticles overcome sequential absorption barriers for oral insulin delivery","volume":"342","author":"Xi","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2024.02.019_bib164","first-page":"303","article-title":"Going below and beyond the surface: microneedle structure, materials, drugs, fabrication, and applications for wound healing and tissue regeneration","volume":"27","author":"Lyu","year":"2023","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib165","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","article-title":"A luminal unfolding microneedle injector for oral delivery of macromolecules","volume":"25","author":"Abramson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.02.019_bib166","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.aau2277","article-title":"An ingestible self-orienting system for oral delivery of macromolecules","volume":"363","author":"Abramson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.02.019_bib167","article-title":"Magneto-responsive microneedle robots for intestinal macromolecule delivery","volume":"33","author":"Zhang","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib168","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1021\/acs.jmedchem.2c00094","article-title":"On the utility of chemical strategies to improve peptide gut stability","volume":"65","author":"Kremsmayr","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.02.019_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.024","article-title":"Physical methods for enhancing drug absorption from the gastrointestinal tract","volume":"175","author":"Luo","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib170","article-title":"Recent advances in oral and transdermal protein delivery systems","volume":"62","author":"Yang","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2024.02.019_bib171","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tem.2017.03.003","article-title":"Unraveling the regulation of hepatic metabolism by insulin","volume":"28","author":"Titchenell","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.apsb.2024.02.019_bib172","article-title":"Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery","volume":"5","author":"Edgerton","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2024.02.019_bib173","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2024.02.019_bib174","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/cells8080881","article-title":"Size Dependency of circulation and biodistribution of biomimetic nanoparticles: red blood cell membrane-coated nanoparticles","volume":"8","author":"Li","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2024.02.019_bib175","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","article-title":"Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles","volume":"31","author":"He","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib176","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.02.019_bib177","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrendo.2014.203","article-title":"Diabetes mellitus and severe mental illness: mechanisms and clinical implications","volume":"11","author":"Holt","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2024.02.019_bib178","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1080\/10717544.2018.1469685","article-title":"Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids","volume":"25","author":"Zhang","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2024.02.019_bib179","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1039\/D1TB00806D","article-title":"Insulin- and cholic acid-loaded zein\/casein-dextran nanoparticles enhance the oral absorption and hypoglycemic effect of insulin","volume":"9","author":"Bao","year":"2021","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2024.02.019_bib180","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1021\/jacs.0c12043","article-title":"Glucagon like peptide 1 receptor agonists for targeted delivery of antisense oligonucleotides to pancreatic beta cell","volume":"143","author":"Knerr","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2024.02.019_bib181","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","article-title":"Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency","volume":"16","author":"Alavi","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2024.02.019_bib182","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/nm.3009","article-title":"Targeted estrogen delivery reverses the metabolic syndrome","volume":"18","author":"Finan","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.02.019_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201809015","article-title":"Phase-changeable nanoemulsions for oral delivery of a therapeutic peptide: toward targeting the pancreas for antidiabetic\u00a0treatments using lymphatic transport","volume":"29","author":"Lin","year":"2019","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2024.02.019_bib184","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1016\/j.biomaterials.2013.07.021","article-title":"Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT","volume":"34","author":"Chuang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2024.02.019_bib185","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41551-021-00791-0","article-title":"Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin","volume":"5","author":"Lee","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2024.02.019_bib186","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41574-021-00542-w","article-title":"One hundred years of insulin therapy","volume":"17","author":"Mathieu","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2024.02.019_bib187","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/1061186X.2020.1759078","article-title":"Current status and applications of animal models in pre-clinical development of orally administered insulin-loaded nanoparticles","volume":"28","author":"Wong","year":"2020","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2024.02.019_bib188","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcjd.2023.05.007","article-title":"The reponic classification of insulin","volume":"47","author":"Moen","year":"2023","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.apsb.2024.02.019_bib189","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrendo.2015.173","article-title":"Impaired insulin action in the human brain: causes and metabolic consequences","volume":"11","author":"Heni","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2024.02.019_bib190","series-title":"Medical Biochemistry","first-page":"264","article-title":"Glucose homeostasis and fuel metabolism: diabetes mellitus","author":"Dominiczak","year":"2014"},{"key":"10.1016\/j.apsb.2024.02.019_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.apsb.2024.02.019_bib192","unstructured":"Administration USFaD. Rybelsus clinical pharmacology review(s). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213182Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.apsb.2024.02.019_bib193","unstructured":"FDAnews. Oramed's ORMD-0801 fails in type 2 diabetes study. Available from: https:\/\/www.fdanews.com\/articles\/210827-orameds-ormd-0801-fails-in-type-2-diabetes-study."}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T23:02:31Z","timestamp":1715900551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":193,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2211383524000571"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.02.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}